Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress

Cellectis announced final Phase 1 results from the BALLI-01 trial of lasme-cel, a CD22-directed allogeneic CAR-T therapy for relapsed/refractory B-cell acute lymphoblastic leukemia, showing 100% overall response rate in the target Phase 2 population with manageable safety profile. The company also presented preliminary data on eti-cel, a dual CD20/CD22 CAR-T for relapsed/refractory B-cell non-Hodgkin lymphoma, demonstrating 88% ORR in the optimal dose cohort. Both therapies are advancing to Phase 2 trials with first interim analyses expected in Q4 2026.